Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
Krystal Biotech announced robust financial results for Q1 2026, including a 32% increase in global revenue for its gene therapy product VYJUVEK, totaling $116.4 million. The company completed enrollment in a key ophthalmology clinical study and is on track for multiple registrational data readouts this year. It also received FDA platform technology…